Innovation Pharmaceuticals IncOver The Counter Market:IPIX
- LAST PRICE0.0030
- TODAY'S CHANGE (%)0.0010 (50.0000%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close0.0001 / 0.0020
- Day Range
- 52 Week Range
- Volume161,805
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | IPIX |
|---|---|---|
| 09:32 ET | 25625 | 0.0001 |
| 09:57 ET | 20000 | 0.002 |
| 10:14 ET | 15950 | 0.002 |
| 02:26 ET | 230 | 0.0023 |
| 03:34 ET | 100000 | 0.003 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Innovation Pharmaceuticals Inc | 1.0M | -0.6x | --- |
GlobeStar Therapeutics Corp | 1.0M | -0.4x | --- |
LadRx Corp | 1.1M | 4.0x | --- |
Evelo Biosciences Inc | 865.1K | 0.0x | --- |
Agentix Corp | 1.3M | -1.3x | --- |
Capstone Holding Corp | 819.6K | -0.8x | --- |
Company Information
Innovation Pharmaceuticals Inc. is a clinical stage pharmaceutical company developing therapies with anti-infective, oncology, anti-inflammatory and dermatology applications. The Company’s lead drug candidate, Brilacidin, is in a class of compounds called defensin-mimetics, small compounds that mimic the structure and function of defensins, also known as host defense peptides. The Company is primarily focused on business development for the advancement of Brilacidin in the treatment of infectious diseases and oral mucositis. Its ongoing activities include Brilacidin drug manufacturing, scientific report writing, and supportive research activities. Brilacidin is also developed as a treatment in more extensive forms of inflammatory bowel disease (IBD). It is engaged in developing an image guided surgical laser platform, through BT BeaMedical Technologies Ltd. It is also engaged in business development and licensing initiatives with specialty and global pharmaceutical companies.
Contact Information
- Headquarters
- 301 EDGEWATER PLACE, SUITE 100WAKEFIELD, MA, United States 01880
- Phone
- 978-921-4125
- Fax
- 978-921-6564
Executives
- Chairman of the Board, Chief Executive Officer, Chief Financial Officer
- Leo Ehrlich
- Senior Vice President - Clinical Sciences and Portfolio Management
- Jane Harness
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.0M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 518.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.03 |
EPS | $0.00 |
Book Value | $0.00 |
P/E Ratio | -0.6x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
